Cargando…
Tumor-Resident Dendritic Cells and Macrophages Modulate the Accumulation of TCR-Engineered T Cells in Melanoma
Ongoing clinical trials explore T cell receptor (TCR) gene therapy as a treatment option for cancer, but responses in solid tumors are hampered by the immunosuppressive microenvironment. The production of TCR gene-engineered T cells requires full T cell activation in vitro, and it is currently unkno...
Autores principales: | Hotblack, Alastair, Holler, Angelika, Piapi, Alice, Ward, Sophie, Stauss, Hans J., Bennett, Clare L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986719/ https://www.ncbi.nlm.nih.gov/pubmed/29628306 http://dx.doi.org/10.1016/j.ymthe.2018.03.011 |
Ejemplares similares
-
Dendritic Cells Cross-Present Immunogenic Lentivector-Encoded Antigen from Transduced Cells to Prime Functional T Cell Immunity
por: Hotblack, Alastair, et al.
Publicado: (2017) -
Engineering CD4+ T Cells to Enhance Cancer Immunity
por: Sillito, Francesca, et al.
Publicado: (2020) -
Human MHC Class I-restricted high avidity CD4(+) T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo
por: Xue, Shao-An, et al.
Publicado: (2013) -
A Study of T Cell Tolerance to the Tumor-Associated Antigen MDM2: Cytokines Can Restore Antigen Responsiveness, but Not High Avidity T Cell Function
por: Bendle, Gavin M., et al.
Publicado: (2007) -
Improving TCR Gene Therapy for Treatment of Haematological Malignancies
por: Nicholson, Emma, et al.
Publicado: (2012)